REG - Destiny Pharma PLC - Posting of Circular and Notice of General Meeting

Destiny PharmaAnnouncement

28/02/2023 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230228:nRSb3892Ra&default-theme=true

RNS Number : 3892R  Destiny Pharma PLC  28 February 2023

28 February 2023

Destiny Pharma plc

Posting of Circular and Notice of General Meeting

Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), is pleased
to confirm that, further to the announcement of 24 February 2023, the
shareholder circular (the "Circular") providing further details of the
Placing, Subscription and the Open Offer and notice of General Meeting has
been posted to shareholders today.

The Circular contains a Notice of General Meeting to be held at the offices of
Covington & Burling LLP, 22 Bishopsgate, London, EC2N 4BQ on 16 March 2023
at 2.00 p.m. (the "General Meeting").  Please note that the time of the
General Meeting has changed from that announced on 24 February 2023.

A copy of the Circular, Open Offer Application Form and Form of Proxy will
shortly be available from the Company's website (www.destinypharma.com).

Unless otherwise defined, all capitalised terms used but not defined in this
announcement shall have the meaning given to them in the Circular.

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

                                                                                                                                                   2023
 Announcement of the Placing, the Open Offer and the Subscription                                                        24 February
 Record Date for entitlements under the Open Offer                                                                       Close of business on 23 February
 Ex-entitlement Date for the Open Offer                                                                                  8.00 a.m. on 27 February
 Posting of the Circular (including the Notice of General Meeting), the Form of                                          28 February
 Proxy and, to Qualifying Non-CREST Shareholders, the Application Form
 Basic Entitlements and Excess Entitlements credited to stock accounts of                                                As soon as possible on 1 March
 Qualifying CREST Shareholders
 First Admission and commencement of dealings in the Placing Shares and the                                              8.00 a.m. on 1 March
 Subscription Shares on AIM
 First Placing Shares in uncertificated form pursuant to First Admission                                                 As soon as possible after 8.00 a.m. on 1 March
 expected to be credited to accounts in CREST
 Recommended latest time and date for requesting withdrawal of Basic                                                     4.30 p.m. on 9 March
 Entitlements and Excess Entitlements from CREST
 Latest time and date for depositing Basic Entitlements and Excess Entitlements                                          3.00 p.m. on 10 March
 into CREST
 Latest time and date for splitting Application Forms (to satisfy bona fide                                              3.00 p.m. on 13 March
 market claims only)
 Latest time and date for receipt of completed Application Forms and payment in                                          11.00 a.m. on 15 March
 full under the Open Offer or settlement of relevant CREST instructions (as
 appropriate)
 Announcement of the results of the Open Offer                                                                           15 March
 Latest time and date for receipt of CREST proxy instructions and registration                                           2.00 p.m. on 14 March
 of online votes from Shareholders for General Meeting
 Latest time and date for receipt of Forms of Proxy                                                                      2.00 p.m. on 14 March
 General Meeting                                                                                                         2.00 p.m. on 16 March
 Announcement of the results of the General Meeting                                                                      16 March
 Second Admission and commencement of dealings in the Committed Open Offer                                               8.00 a.m. on 17 March
 Shares on AIM
 Committed Open Offer Shares in uncertificated form pursuant to Second                                                   As soon as possible after 8.00 a.m. on 17 March
 Admission expected to be credited to accounts in CREST (uncertificated holders
 only)
 Dispatch of definitive share certificates for the New Shares in certificated  Within 5 business days of
 form
First Admission, or Second

                                                                               Admission, where applicable

 

Each of the times and dates above refer to London time and are subject to
change at the absolute discretion of the Company, finnCap and Shore Capital.
Any such change will be notified to Shareholders by an announcement through a
Regulatory Information Service. Certain of the events in the above timetable
are conditional upon, inter alia, the approval of the Resolutions to be
proposed at the General Meeting.

 

 

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Optimum Strategic Communications

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGKZGZZKRDGFZM